
Roche’s cancer pill Erivedge has received a conditional European approval for treatment of the most common type of skin cancer. …

Roche’s skin cancer candidate vismodegib has met its primary endpoint in a phase II trial. The drug is being tested …
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions

